Original research article| Volume 89, ISSUE 5, P352-356, May 2014

Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate



      To evaluate feasibility, acceptability, continuation, and trough serum levels following self-administration of subcutaneous (sc) depot medroxyprogesterone acetate (DMPA).

      Study design

      Women presenting to a family planning clinic to initiate, restart or continue DMPA were offered study entry. Participants were randomized in a 2:1 ratio to self- or clinician administered sc DMPA 104 mg. Those randomized to self-administration were taught to self-inject and were supervised in performing the initial injection; they received printed instructions and a supply of contraceptive injections for home use. Participants randomized to clinician administration received usual care. Continued DMPA use was assessed by self-report and trough medroxyprogesterone acetate levels at 6 and 12 months.


      Two hundred fifty women were invited to participate, and 137 (55%) enrolled. Of these, 91 were allocated to self-administration, and 90/91 were able to correctly self-administer sc DMPA. Eighty-seven percent completed follow-up. DMPA use at 1 year was 71% for the self-administration group and 63% for the clinic group (p=0.47). Uninterrupted DMPA use was 47% and 48% for the self and clinic administration groups at 1 year (p=0.70), respectively. Serum analyses confirmed similar mean DMPA levels in both groups and therapeutic trough levels in all participants.


      Sixty-three percent of women approached were interested in trying self-administration of DMPA, even in the context of a randomized trial, and nearly all eligible for enrollment were successful at doing so. Self-administration and clinic administration resulted in similar continuation rates and similar DMPA serum levels. Self-administration of sc DMPA is feasible and may be an attractive alternative for many women.


      Self-administration of sc DMPA is a feasible and attractive option for many women. Benefits include increased control over contraceptive measures and less time spent on contracepting behaviors. Globally, self-administration has the potential to revolutionize contraceptive uptake by increasing the number of women with access to DMPA.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Frost J.J.
        • Darroch J.E.
        • Remez L.
        Improving contraceptive use in the United States.
        in: Brief. Guttmacher Institute, New York2008
        • Moreau C.
        • Cleland K.
        • Trussell J.
        Contraceptive discontinuation attributed to method dissatisfaction in the United States.
        Contraception. 2007; 76: 267-272
        • Paul C.
        • Skegg D.C.G.
        • Williams S.
        Depot medroxyprogesterone acetate: Patterns of use and reasons for discontinuation.
        Contraception. 1997; 56: 209-214
        • Polaneczky M.
        • Liblanc M.
        Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents.
        J Adolesc Health. 1998; 23: 81-88
        • Bahamondes L.
        • Marchi N.M.
        • Nakagava H.M.
        • De Melo M.L.
        • Cristofoletti Mde L.
        • Pellini E.
        • et al.
        Self-administration with UniJect of the once-a-month injectable contraceptive Cyclofem.
        Contraception. 1997; 56: 301-304
        • Prabhakaran S.
        • Sweet A.
        Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability.
        Contraception. 2012; 85: 453-457
        • Cameron S.T.
        • Glasier A.
        • Johnstone A.
        Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception.
        Contraception. 2012; 85: 458-464
        • Williams R.L.
        • Hensel D.J.
        • Fortenberry J.D.
        Self-administration of subcutaneous depot medroxyprogesterone acetate by adolescent women.
        Contraception. 2013; 88: 401-407
        • World Health Organization
        Medical eligibility criteria for contraceptive use. WHO Press, Geneva2004 (Available from:)
        • Rickert V.I.
        • Tiezzi L.
        • Lipshutz J.
        • Leon J.
        • Vaughan R.D.
        • Westhoff C.
        Depo now: preventing unintended pregnancies among adolescents and young adults.
        J Adolesc Health. 2007; 40: 22-28
        • Pfizer
        depo-subQ provera 104(r) medroxyprogesterone acetate injectable suspension 104 mg/0.65 mL: physician information. Pharmacia and Upjohn Company, New York2009 (Available from:)
        • Estes C.M.
        • Ramierez J.
        • Tiezzi L.
        • Westhoff C.
        Self pregnancy testing in an urban family planning clinic: promising results for a new approach to contraceptive follow-up.
        Contraception. 2008; 77: 40-43
        • Ortiz A.
        • Hiroi M.
        • Stanczyk F.Z.
        • Goebelsmann U.
        • Mishell D.R.
        Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of Depo-MPA.
        J Clin Endocrinol Metab. 1977; 44: 32-39
        • Mishell D.R.
        Pharmacokinetics of depot medroxyprogesterone acetate contraception.
        J Reprod Med. 1996; 41: 381-390
        • Picardo C.
        • Ferreri S.
        Pharmacist-administered subcutaneous depot medroxyprogesterone acetate: a pilot randomized controlled trial.
        Contraception. 2010; 82: 160-167
        • Lakha F.
        • Henderson C.
        • Glasier A.
        The acceptability of self-administration of subcutaneous Depo-Provera.
        Contraception. 2005; 72: 14-18
        • Stanwood N.L.
        • Eastwood K.
        • Carletta A.
        Self-injection of monthly combined hormonal contraceptive.
        Contraception. 2006; 73: 53-55
        • Koetsawang S.
        • Shrimanker K.
        • Fotherby K.
        Blood levels of medroxyprogesterone acetate after multiple injections of DepoProvera or CycloProvera.
        Contraception. 1979; 20: 1-4
        • Keith B.
        Home-based administration of depo-subQ provera 104(tm) in the Uniject(tm) Injection System: A literature Review.
        Seattle, PATH2011